Advances in Cancer Research

Erscheinungsjahr 2016
ISBN: 978-0-12-804788-0
Verlag: William Andrew Publishing

Buch, Englisch, 208 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 540 g

Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics.

Autoren/Hrsg.

Weitere Mitwirkende

Tew, Kenneth D.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung

Inhaltsverzeichnis

1. The Dual Role of Senescence in Pancreatic Ductal AdenocarcinomaAngelo Porciuncula, Cristina Hajdu and Gregory David2. Small Molecule Targeting of BET Proteins in CancerChristopher A. French3. H3K27 Methylation: A Focal Point of Epigenetic Deregulation in CancerJessica N. Nichol, Daphné Dupéré-Richer, Teresa Ezponda, Jonathan D. Licht, Wilson H. Miller and Jr.4. AEG1/MTDH/LYRIC: A Promiscuous Protein Partner Critical in Cancer, Obesity and CNS DiseasesLuni Emdad, Swadesh K. Das, Bin Hu, Timothy Kegelman, Dong-chul Kang, Seok-Geun Lee, Devanand Sarkar and Paul B. Fisher5. Role of the RB Interacting Proteins in Stem Cell BiologyM. Mushtaq, H. Viñas Gaza and E.V. Kashuba6. Evolving Strategies for Therapeutically Targeting Cancer Stem Cells (CSCs)Sarmistha Talukdar, Luni Emdad, Swadesh K. Das, Devanand Sarkar and Paul B. Fisher

Über Autor(innen)

Tew, Kenneth D.
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.